The global cardiovascular drugs market size is expected to reach around US$ 91.7 Bn by 2026 and is anticipated to register CAGR of over 1.0% from 2019 to 2026.
The demand within the global cardiovascular drugs market is expected to rise in the years to follow. The aforementioned projection is based on the rising incidence of heart diseases, strokes, and cardiac arrests. The field of cardiology has become the cynosure of the healthcare industry, and regional governments have made heavy investments in this sector. Furthermore, the sedentary lifestyles of the masses have made them laid back and sluggish. This trend has become the leading cause of cardiovascular diseases across the world. The quest of the medical fraternity to educate the masses about the importance of a balanced and healthy lifestyle is a key trend within the healthcare industry.
Focus on Critical Care to Stabilize Market Growth
It is of imperative value to administer the best form of treatment for patients suffering from cardiac diseases. The heart is the most critical body organ, and research related to the heart’s functionality has always held an upper hand in medicine. Therefore, the global cardiovascular drugs market is set to attract a huge amount of revenues in the following years. The hereditary nature of several cardiac diseases has added to the worries of the medical professionals.
However, availability of improved drugs and cardiac-care technologies have been a matter of relief for the global medical industry. Prescription of cardiovascular drugs is not expected to run out of practice due to their indispensability for heart patients. Furthermore, there are no invasive procedures or alternative medications that can substitute the use of cardiovascular drugs.
Increasing Incidence of Cardiac Diseases
Lack of physical activity is considered as the leading cause of cardiovascular diseases. Furthermore, the eating habits of the people have changed abysmally, and this has affected the global healthcare index. Demand for junk food and oily cuisines is on a rise, and this is an adverse indicator for the healthcare industry. Considering the factors mentioned above, it is safe to expect that the global cardiovascular drugs market would expand a stellar pace in the years to follow.
The vendors operating in the global cardiovascular drugs market are projected to invest in online marketing. Market players such as Bayer AG, Pfizer, and Novartis are creating awareness campaigns around healthy food habits and exercise routines. These indirect forms of marketing are expected to play a key role in the growth of these market vendors.
The report analyzes and forecasts the cardiovascular drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of cardiovascular drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major cardiovascular drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of cardiovascular drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of cardiovascular drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global cardiovascular drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the cardiovascular drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of cardiovascular drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the cardiovascular drugs market are AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceuticals Company Limited and others.
The global cardiovascular drugs market has been segmented as follows:
Cardiovascular Drugs Market, by Drug Class
Cardiovascular Drugs Market, by Indication
Cardiovascular Drugs Market, by Distribution Channel
Cardiovascular Drugs Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global CVD Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Overview
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global CVD Market Analysis and Forecasts, 2017–2026
4.5.3. Market Revenue Projections (US$ Mn)
4.6. CVD Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.9. Market Outlook
5. Global CVD Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.4. Market Value Forecast By Drug Class , 2017–2026
5.4.1. Renin-Angiotensin System Blockers
5.4.1.1. ACE Inhibitors
5.4.1.2. Angiotensin Receptor Blockers
5.4.2. Beta Blockers
5.4.3. Diuretics
5.4.4. Anti-Clotting Agents
5.4.4.1. Anti-Coagulants
5.4.4.2. Platelet Aggregation Inhibitors
5.4.5. Antihyperlipidemics
5.4.6. Other Antihypertensives
5.4.7. Calcium Channel Blockers
5.4.8. Others
5.5. Market Attractiveness By Drug Class
6. Global CVD Market Analysis and Forecasts, By Indications
6.1. Introduction & Definition
6.2. Key Findings
6.4. Market Value Forecast By Indications , 2017–2026
6.4.1. Hypertension
6.4.2. Hyperlipidemia
6.4.3. Coronary Artery Disease
6.4.4. Peripheral Artery Disease
6.4.5. Arrhythmia
6.4.6. Others
6.5. Market Attractiveness By Indications
7. Global CVD Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.4. Market Value Forecast By Distribution Channel , 2017–2026
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Market Attractiveness By Distribution Channel
8. Global CVD Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region
9. North America CVD Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Class , 2017–2026
9.2.1. Renin-Angiotensin System Blockers
9.2.1.1. ACE Inhibitors
9.2.1.2. Angiotensin Receptor Blockers
9.2.2. Beta Blockers
9.2.3. Diuretics
9.2.4. Anti-Clotting Agents
9.2.4.1. Anti-Coagulants
9.2.4.2. Platelet Aggregation Inhibitors
9.2.5. Antihyperlipidemics
9.2.6. Other Antihypertensives
9.2.7. Calcium Channel Blockers
9.2.8. Others
9.3. Market Value Forecast By Indications , 2017–2026
9.3.1. Hypertension
9.3.2. Hyperlipidemia
9.3.3. Coronary Artery Disease
9.3.4. Peripheral Artery Disease
9.3.5. Arrhythmia
9.3.6. Others
9.4. Market Value Forecast By Distribution Channel , 2017–2026
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Market Value Forecast By Country , 2017–2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Indications
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe CVD Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast By Drug Class , 2017–2026
10.2.1. Renin-Angiotensin System Blockers
10.2.1.1. ACE Inhibitors
10.2.1.2. Angiotensin Receptor Blockers
10.2.2. Beta Blockers
10.2.3. Diuretics
10.2.4. Anti-Clotting Agents
10.2.4.1. Anti-Coagulants
10.2.4.2. Platelet Aggregation Inhibitors
10.2.5. Antihyperlipidemics
10.2.6. Other Antihypertensives
10.2.7. Calcium Channel Blockers
10.2.8. Others
10.3. Market Value Forecast By Indications , 2017–2026
10.3.1. Hypertension
10.3.2. Hyperlipidemia
10.3.3. Coronary Artery Disease
10.3.4. Peripheral Artery Disease
10.3.5. Arrhythmia
10.3.6. Others
10.4. Market Value Forecast By Distribution Channel , 2017–2026
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Market Value Forecast By Country , 2017–2026
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indications
10.6.3. By Distribution Channel
10.6.4. By Country
11. Asia Pacific CVD Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class , 2017–2026
11.2.1. Renin-Angiotensin System Blockers
11.2.1.1. ACE Inhibitors
11.2.1.2. Angiotensin Receptor Blockers
11.2.2. Beta Blockers
11.2.3. Diuretics
11.2.4. Anti-Clotting Agents
11.2.4.1. Anti-Coagulants
11.2.4.2. Platelet Aggregation Inhibitors
11.2.5. Antihyperlipidemics
11.2.6. Other Antihypertensives
11.2.7. Calcium Channel Blockers
11.2.8. Others
11.3. Market Value Forecast By Indications , 2017–2026
11.3.1. Hypertension
11.3.2. Hyperlipidemia
11.3.3. Coronary Artery Disease
11.3.4. Peripheral Artery Disease
11.3.5. Arrhythmia
11.3.6. Others
11.4. Market Value Forecast By Distribution Channel , 2017–2026
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Market Value Forecast By Country , 2017–2026
11.5.1. Japan
11.5.2. China
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indications
11.6.3. By Distribution Channel
11.6.4. By Country
12. Latin America CVD Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class , 2017–2026
12.2.1. Renin-Angiotensin System Blockers
12.2.1.1. ACE Inhibitors
12.2.1.2. Angiotensin Receptor Blockers
12.2.2. Beta Blockers
12.2.3. Diuretics
12.2.4. Anti-Clotting Agents
12.2.4.1. Anti-Coagulants
12.2.4.2. Platelet Aggregation Inhibitors
12.2.5. Antihyperlipidemics
12.2.6. Other Antihypertensives
12.2.7. Calcium Channel Blockers
12.2.8. Others
12.3. Market Value Forecast By Indications , 2017–2026
12.3.1. Hypertension
12.3.2. Hyperlipidemia
12.3.3. Coronary Artery Disease
12.3.4. Peripheral Artery Disease
12.3.5. Arrhythmia
12.3.6. Others
12.4. Market Value Forecast By Distribution Channel , 2017–2026
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Market Value Forecast By Country , 2017–2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indications
12.6.3. By Distribution Channel
12.6.4. By Country
13. Middle East & Africa CVD Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class , 2017–2026
13.2.1. Renin-Angiotensin System Blockers
13.2.1.1. ACE Inhibitors
13.2.1.2. Angiotensin Receptor Blockers
13.2.2. Beta Blockers
13.2.3. Diuretics
13.2.4. Anti-Clotting Agents
13.2.4.1. Anti-Coagulants
13.2.4.2. Platelet Aggregation Inhibitors
13.2.5. Antihyperlipidemics
13.2.6. Other Antihypertensives
13.2.7. Calcium Channel Blockers
13.2.8. Others
13.3. Market Value Forecast By Indications , 2017–2026
13.3.1. Hypertension
13.3.2. Hyperlipidemia
13.3.3. Coronary Artery Disease
13.3.4. Peripheral Artery Disease
13.3.5. Arrhythmia
13.3.6. Others
13.4. Market Value Forecast By Distribution Channel , 2017–2026
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Market Value Forecast By Country , 2017–2026
13.5.1. South Africa
13.5.2. GCC Region
13.5.3. Israel
13.5.4. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indications
13.6.3. By Distribution Channel
13.6.4. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Merck & Co. Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Bristol-Myers Squibb Company
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Bayer AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Boehringer Ingelheim GmbH
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. F. Hoffmann-La Roche Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Abbott Laboratories
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Gilead Sciences, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Johnson & Johnson
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Astellas Pharma, Inc.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. Eli Lilly and Company
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Financial Overview
14.3.14.3. Product Portfolio
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
14.3.15. Otsuka Holdings Co., Ltd.
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Financial Overview
14.3.15.3. Product Portfolio
14.3.15.4. SWOT Analysis
14.3.15.5. Strategic Overview
14.3.16. Takeda Pharmaceuticals Company Limited
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Financial Overview
14.3.16.3. Product Portfolio
14.3.16.4. SWOT Analysis
14.3.16.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers